SOURCE-LINKED STUDY SUMMARY
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Abstract summarizedQuality not appraised
- What was studied
- A trial separated changes in appetite and food intake from an indirect measure of stomach emptying.
- Who / model studied
- 72 adults with obesity, randomized to semaglutide or placebo.
- Studied dose & schedule
- Once-weekly subcutaneous semaglutide, escalated to 2.4 mg, or placebo for 20 weeks.
- What the study found
- At the test lunch, energy intake was 35% lower with semaglutide. Hunger and cravings decreased; fullness increased. Body weight fell 9.9% versus 0.4% with placebo. No delayed gastric emptying was detected at week 20.
- Limitations & context
- Gastric emptying was measured indirectly by paracetamol absorption. This result does not rule out delayed emptying earlier in treatment or under other conditions. Lunch intake is not total daily intake.
Read summary source ↗ · Prepared 9/29/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/dom.14280